Skip to content

Health and Life Sciences

We know the Health and Life Sciences Industry. We serve our clients with a commanding combination of courtroom mastery, business acumen, creative problem-solving and our unrivaled scientific and financial expertise. From Hatch-Waxman ANDA and 505(b)(2) litigation to health care payor disputes, we devise creative winning strategies in complex litigation, intellectual property, fraud, antitrust, and other commercial disputes. We help you safeguard your business and your bottom line by aligning legal strategy to expeditiously resolve your business needs. Our health and life sciences attorneys prepare the most effective representation possible using insights from our in-house Ph.D. economists and scientists, along with advanced project management, budgeting, and communication tools. Together, these resources married with our depth of experience give our life science and health clients a competitive advantage and allow them to focus on driving their business forward.

Health and Life Sciences Experience

Patent Litigation
  • 505(b)(2) new drugs
  • Biopharmaceuticals and biologics
  • Biotechnology
  • Clean technologies
  • Generics
  • Medical devices
  • PTAB and ITC proceedings

Trial-born knowledge of patent infringement recovery, patent litigation defense, and key industry technologies

Hatch-Waxman Litigation
  • ANDA counseling
  • Generic pharmaceutical manufacturers
  • Innovator pharmaceutical companies

Trial litigation and technical breadth offering clients a big-picture perspective for disputes under Hatch-Waxman

Biotech IP Assessment
  • Cost-certain initial and landscape phases
  • Strategic litigation options
  • Health IT

Helping biotech companies view and value their product portfolios and licensing agreements through the lens of litigation

Trade Secret
  • Misappropriation of confidential information
  • Trade show protection best practices
  • Protection/prevention counseling

Safeguarding clients’ proprietary information and processes through all stages of litigation

Trademark, Brand, and Advertising Litigation
  • Competitor disputes
  • Consumer labelling actions
  • False Claims Act

Vigorous protection of key brand assets from infringement and unfair competition

Privacy and Cyber Security Litigation
  • Mobile health risks
  • “Big Data” and PII privacy rules, e.g., HIPAA

Trial-proven tactics that enable an aggressive, rapid response to information privacy law and cyber security law challenges

Corporate Compliance and Ethics
  • Compliance with Drug Quality and Security Act
  • Internal investigations
  • FDA regulatory requirements
  • Antitrust, Stark, anti-kickback
  • Data privacy and security

Delivering the critical components needed to make compliance programs work

Antitrust and Trade Regulation
  • Generic “reverse-payment” exposure
  • Vertical integration risks
  • Foreign Corrupt Practices Act
  • Health care industry consolidation

Innovative and sophisticated antitrust counseling and litigation representation

Business Litigation
  • Complex contractual disputes
  • Investor/financial litigation
  • Appellate advocacy
  • Class action pursuit and defense
  • Global business and technology sourcing disputes

An impressive track record of resolving complex legal and business challenges

Insurance/Provider and Provider Network Disputes
  • Network participation
  • Network discounts
  • Out-of-network reimbursement
  • Claim review and adjudication
  • Mental health parity
  • Silent PPO claims

Serving clients in both affirmative and defensive engagements in single, multi-party, and class actions as well as complex arbitrations

View All »

Health and Life Sciences Case Results

Antitrust and Trade Regulation
Class Action Litigation
Hatch-Waxman Litigation
Patent Litigation
Payor Litigation
Trademark, Advertising, and Brand Litigation
Trade Secret

Health and Life Sciences Resources


March 13, 2015

Venue’s potential dramatic impact on Hatch-Waxman Act litigation.


July 24, 2015

The Second Circuit’s decision in New York v. Actavis could impact antitrust law both inside and outside the pharmaceutical industry.


Fall 2016

Some brand-name drug manufacturers have used various tactics—some lawful and some arguably unlawful—in an effort to delay generic competition and maintain monopoly profits.